Biobank of Data and of Human Biological Samples on Prematurity, Preeclampsia and Other Pregnancy Complications
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
The Biobank includes data and biological specimens of women from three original studies: 1) First-trimester Prediction of Preeclampsia (PREDICTION Study, NCT02189148), 2) Pre-Eclampsia And growth Retardation, an evaluative Longitudinal study (PEARL Study, NCT02379832), 3) Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial (NCT02280031) and 4)PREDICTION2: Prediction of Preeclampsia and other Pregnancy Complications Following Combined Iterative Screening.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: t
View:
• (specific to each study)
Locations
Other Locations
Canada
CHU de Quebec
RECRUITING
Québec
Contact Information
Primary
Emmanuel Bujold, MD, MSc
emmanuel.bujold@crchudequebec.ulaval.ca
418-525-4444
Backup
Sylvie Tapp, MSc
sylvie.tapp@crchudequebec.ulaval.ca
418-525-4444
Time Frame
Start Date: 2015-04
Estimated Completion Date: 2028-04
Participants
Target number of participants: 7845
Treatments
Prediction Group
The women recruited in the biobank through the Prediction Study (NCT02189148) are low-risk pregnant women between 11 and 13 6/7 weeks of gestation (N=7600 maximum).
PEARL Group
The women recruited in the biobank through the PEARL Study (NCT02379832) are :~1. low-risk pregnant women between 11 and 13 6/7 weeks of gestation (controls, N=45)~2. pregnant women with diagnosis of preeclampsia between 20 and 41 6/7 weeks of gestation (cases, N=45)
GAP Group
The women recruited in the biobank through the GAP Trial (NCT02280031) are women pregnant with twins between 11 3/7 and 13 6/7 weeks of gestation(N=50 maximum) randomized for placebo or aspirin.
PREDICTION 2 Group
The women recruited in the biobank through the Prediction-2 Study (NCT03067298) are nulliparous pregnant women between 14 and 15 6/7 weeks of gestation (N=1000 maximum).
HAUPE Study
Women that are at risk of pre-eclampsia and great obstetrical syndroms (elevated maternal age, invitro fertilization, chronic disease) (N=60) and a control group not at risk (N=60)
Related Therapeutic Areas
Sponsors
Leads: CHU de Quebec-Universite Laval